[
    [
        {
            "time": "",
            "original_text": "上海医药(02607-HK)获核准增发不超过约1.84亿股境外上市外资股",
            "features": {
                "keywords": [
                    "上海医药",
                    "核准",
                    "增发",
                    "境外上市外资股"
                ],
                "sentiment_score": 0.7,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "上海医药(02607-HK)获核准增发不超过约1.84亿股境外上市外资股",
                "Correlation": 10,
                "Sentiment": 5,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "上海医药(02607.HK)控股股东上实集团增持20万股H股",
            "features": {
                "keywords": [
                    "上海医药",
                    "控股股东",
                    "上实集团",
                    "增持",
                    "H股"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "上海医药(02607.HK)控股股东上实集团增持20万股H股",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "上海医药(601607.SH)非公开发行境外上市外资股(H股)获中国证监会核准",
            "features": {
                "keywords": [
                    "上海医药",
                    "非公开发行",
                    "境外上市外资股",
                    "H股",
                    "中国证监会",
                    "核准"
                ],
                "sentiment_score": 0.75,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "上海医药(601607.SH)非公开发行境外上市外资股(H股)获中国证监会核准",
                "Correlation": 10,
                "Sentiment": 5,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        }
    ]
]